ABSTRACT
Placenta is the only link between the pregnant woman and fetus, and the basis for maintaining the normal pregnancy process and fetal development. Maternal stress is the maternal physiological and psychological changes caused by various factors, characterized by the increased level of glucocorticoid, which affects the hypothalamic-pituitary-target gland axis and regulates the expression of target genes. Maternal stress also changes the weight, metabolism and nutrient transportation of the placenta, which will substantially influence the development of fetus. This paper will firstly summarize the characteristics of maternal stress and its influence on offspring. Then, the changes in the body under maternal stress will be described. Finally, we will clarify the proven mechanisms underlying maternal stress and raise some important problems that have not been clarified in this area. The study of maternal stress on fetus and its underlying mechanisms will serve as theoretical basis for the diagnosis and treatment of the stress-related pregnant diseases and disorders.
Subject(s)
Female , Humans , Pregnancy , Fetal Development , Fetus , PlacentaABSTRACT
Objective: To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features. Methods: The GCBI database was used to analyse the MTA2 expression in most cancers. Immunohistochemical staining of MTA2, p53, ER, PR and Ki- 67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria. And the correlation between MTA2 expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER, PR, p53 or Ki-67. Results: The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database. MTA2 was overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000), and the expression level was related to tumor grade (χ2=8.072, P=0.018) and Ki-67 expression (r=0.227, P=0.013). Conclusion: MTA2 may act as an oncogene in endometrial carcinomas, and it is a promising target for diagnosis and treatment of endometrial carcinomas.
ABSTRACT
Objective·To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features.Methods·The GCBI database was used to analyse the MTA2 expression in most cancers.Immunohistochemical staining of MTA2,p53,ER,PR and Ki-67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria.And the correlation between MTA2 expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER,PR,p53 or Ki-67.Results·The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database.MTA2 was overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000),and the expression level was related to tumor grade (x2=8.072,P=0.018) and Ki-67 expression (r=0.227,P=0.013).Conclusion·MTA2 may act as an oncogene in endometrial carcinomas,and it is a promising target for diagnosis and treatment of endometrial carcinomas.